Immuno-Based Botulinum Toxin Serotype A Activity Assays

Patent No. EP2271670 (titled "Immuno-Based Botulinum Toxin Serotype A Activity Assays") was filed by Allergan on Mar 13, 2009. The application was issued on Sep 3, 2014.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
IPSEN PHARMAJun 2, 2015CABINET PLASSERAUD
MERZ PHARMAJun 2, 2015HERZOG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2271670

ALLERGAN
Application Number
EP09719709A
Filing Date
Mar 13, 2009
Status
Opposition Rejected
May 12, 2021
Publication Date
Sep 3, 2014